Cargando…
A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo
Leukemia cells highly expressing chemokine receptor CXCR4 can actively response to stroma derived factor 1α (CXCL12), trafficking and homing to the marrow microenvironment, which causes poor prognosis and relapse. Here we demonstrate that a novel designed peptide (E5) targeting CXCR4 inhibits CXCL12...
Autores principales: | Li, Xiaojin, Guo, Hua, Yang, Yanlian, Meng, Jie, Liu, Jian, Wang, Chen, Xu, Haiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196105/ https://www.ncbi.nlm.nih.gov/pubmed/25312253 http://dx.doi.org/10.1038/srep06610 |
Ejemplares similares
-
Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis
por: Li, Xiaojin, et al.
Publicado: (2015) -
Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression
por: Guo, Hua, et al.
Publicado: (2017) -
Priapism due to chronic myelocytic leukemia
por: Syarif, et al.
Publicado: (2021) -
In vivo and in vitro effects of heme oxygenase-1 silencing on the survival of acute myelocytic leukemia-M2 cells
por: WEI, SIXI, et al.
Publicado: (2015) -
Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5
por: Fang, Xiaocui, et al.
Publicado: (2017)